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Malcolm E. Molyneux, FMedSci,a,c and Calman A. MacLennan, DPhil, FRCPatha,b,d,f Blantyre, Malawi, and Liverpool, Oxford,
and Birmingham, United KingdomBackground: CD41T lymphocyte measurements are the most
important indicator of mortality in HIV-infected individuals in
resource-limited settings. There is currently a lack of
comprehensive immunophenotyping data from African
populations to guide the immunologic assessmentofHIVinfection.
Objective: To quantify variation in absolute and relative
lymphocyte subsets with age in healthy Malawians.
Methods: Lymphocyte subsets in peripheral blood of 539
healthy HIV-uninfected Malawians stratified by age were
enumerated by flow cytometry.
Results: B and T–lymphocyte and T-lymphocyte subset
absolute concentrations peaked in early childhood then
decreased to adult levels, whereas lymphocyte subset
proportions demonstrated much less variation with age. Adult
lymphocyte subsets were similar to those in developed
countries. In contrast, high B-lymphocyte and
CD81T-lymphocyte levels among children under 2 years,
relative to those in developed countries, resulted in low
CD41T-lymphocyte percentages that varied little between
0 and 5 years (35% to 39%). The CD41T-lymphocyte
percentages in 35% of healthy children under 1 year and 18%
of children age 1 to 3 years were below the World Health
Organization threshold defining immunodeficiency in
HIV-infected children in resource-limited settings. Thirteen
percent of healthy children under 18 months old had a
CD4:CD8T-lymphocyte ratio <1.0, which is commonly
associated with HIV infection. All immunologic parameters
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CD41T-lymphocyte counts were higher in females than males.
Conclusion: Although lymphocyte subsets in Malawian adults
are similar to those from developed countries,
CD41T-lymphocyte percentages in young children are
comparatively low. These findings need to be considered when
assessing the severity of HIV-related immunodeficiency in
African children under 3 years. (J Allergy Clin Immunol
2010;125:203-8.)
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There has been a rapid expansion in the numbers of HIV-
infected individuals commencing antiretroviral therapy (ART) in
Malawi1 and elsewhere in sub-Saharan Africa. Eligibility for
ART has been heavily reliant on HIV/AIDS clinical staging crite-
ria,1,2 but we and others have shown that this is a poor indicator of
immunosuppression.3,4 There has been a steady increase in the
use of CD41 T-lymphocyte enumeration (CD4 counting) by
flow cytometry to guide clinical decision-making in the manage-
ment of HIV infection in Africa. Although regarded by some as
inappropriate in resource-limited settings,1 we and others have
demonstrated that flow cytometry can be both inexpensive and
straightforward to use.3,5-8 CD41 T-lymphocyte numbers have
been shown to be the most important indicator of mortality in
resource-limited settings, particularly among children.9
The accurate interpretation of immunophenotyping data,
including CD4 counts, is reliant on age-specific lymphocyte
subset reference values from healthy individuals in the relevant
population. This is especially important for young children,
because lymphocyte subsets vary markedly with age during
childhood.10-13Well established reference values are available for
the developed world11-14 but are lacking for resource-limited set-
tings, especially Africa. Previous immunophenotyping reference
values from Africa have often had limited subject numbers and
broad age groups15,16 and been restricted to adult subjects17-20
and enumeration of CD41 and CD81 T-lymphocyte subsets.16,21
Current World Health Organization (WHO) guidelines for the
immunologic assessment of HIV-infected children in resource-
limited settings are based on studies from developed coun-
tries.2,22,23 These studies may not be applicable to the developing
world, where genetic and environmental factors, particularly
exposure to infectious diseases, are different. In this study we
present reference lymphocyte subset ranges derived from
539 healthy individuals from Malawi.
METHODS
Study design
The study was conducted at the Ndirande Health Centre, Ndirande
township, Blantyre, Malawi, between October and December 2005 and203
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204 MANDALA ET ALAbbreviations usedART: Antiretroviral therapyNK: Natural killerWHO: World Health OrganizationSeptember and November 2006. Subjects were healthy volunteers from the
township and were made aware of the study by health care assistants at
immunization clinics and by local leaders in the community. Each individual
was assessed clinically by a research nurse and clinical officer for eligibility to
take part in the study. This included a review of each participant’s health
passport, a medical history, and a clinical examination. In particular, partic-
ipants were assessed for signs of febrile illness and active infection, malnu-
trition, and clinical AIDS. Participants were asked whether they were on any
medication and whether they had a history of any illnesses. Approximately 50
subjects were recruited into each of 11 groups according to age: 0 to 6, 6 to 12,
12 to 18, and 18 to 24months, and 2 to 3, 3 to 5, 5 to 10, 10 to 15, 15 to 20, 20 to
60, and over 60 years. After informed consent, baseline demographic data,
height, weight, and a 5-mL blood sample were obtained. A follow-up
appointment was offered 1 week later to give results. HIV-infected adults
and children were referred to the ART clinic.Investigations and flow cytometry
Investigations were performed on EDTA-anticoagulated blood on the day
of venesection at the Blantyre Malaria Project/Ndirande Health Centre and
Malawi-Liverpool-Wellcome Trust Clinical Research Programme. Two HIV
rapid tests, Determine (Abbott Laboratories, Tokyo, Japan) and UniGold
(Trinity Biotech, Dublin, Ireland), were performed. Positive results in children
under 18 months and discordant results were confirmed by PCR as previously
described.24 A malaria parasite slide was prepared, and full blood count and
white cell differential were performed on a HMX hematologic analyzer
(Beckman Coulter, Fullerton, Calif).
For immunophenotyping, 25 mL blood was labeled with 4 mAbs in 2 tubes.
Tube 1 contained T cell receptor (TCR)-gd–fluorescein isothiocyanate,
CD16/CD56-phycoerythrin, CD3-PerCP, and CD8-allophycocyanin (APC).
Tube 2 contained CD4–fluorescein isothiocyanate, CD27-phycoerythrin, CD3-
peridin chlorophyll protein (PerCP), and CD19-APC (all Becton Dickson, San
Jose, Calif). Red cells were lysed by using FACSlysing solution (Becton Dickin-
son) and samples washed with PBS. Sample data were acquired by using a
FACSCalibur flow cytometer (Becton Dickinson). Daily calibration and internal
quality assurance of the instrument was performed by using Calibrite Beads and
FACSComp software (both Becton Dickinson). Sample internal quality assur-
ance involved confirming that the sumof T, B, and natural killer (NK) subset per-
centages was within 100% 6 6%. External quality assurance was undertaken
through the United Kingdom National External Quality Assurance Scheme
(UK NEQAS) immune monitoring scheme.25 Intra-assay and interassay coeffi-
cients of variation were 5.2% and 10.3%, respectively, for absolute CD41
T-lymphocyte counts and 2.5% and 7.3% for CD41 T-lymphocyte percentages.
Sample data were analyzed by using CellQuest software (Becton
Dickinson). Total lymphocytes were identified by light scatter characteristics
and the following lymphocyte subpopulations identified as percentages of the
lymphocyte gate: T cells (CD31), CD41 T cells (CD31CD41), CD81 T cells
(CD31CD81), gdT cells (CD31TCRgd1), B cells (CD191), memory B cells
(CD191CD271), andNK cells (CD3-CD16/561). Lymphocyte subpopulation
concentrations were determined from subpopulation percentages and total
lymphocyte counts from the hematologic analyzer.Exclusions
Subject exclusion criteria were concurrent illness and/or medication,
axillary temperature >38 8C, severe malnutrition (weight-for-height < 70%
in children or body mass index <16% in adults), unknown date of birth, and
known HIV/AIDS. Blood samples were rejected if they were HIV-infected, if
malaria parasites were present, or if the sample was clotted or was not
processed on the day of venesection.Statistical analysis
Medians and 10th and 90th centiles were determined for absolute and
percentage lymphocyte subset concentrations in each age group. All immu-
nologic values were log-transformed, and regression analyses were used to
assess a linear association with age. The effect of sex was explored by
including sex as a term in the regression analysis and by comparing geometric
means for each parameter by sex in each age group. Sex was also included as
an interaction term in the regression analyses to identify any age-related
effects of sex. All statistical analyses were undertaken by using Stata 10
(Stata Corp, College Station, Tex).Ethical approval
The study was approved by the College of Medicine Research and Ethics
Committee of the University of Malawi.RESULTS
Characteristics of study subjects
We recruited 657 subjects (52-75 per group), of whom 341
(53%) were female. The median age was 53.5 months (range, 2
weeks to 92 years). Sixteen withdrew when the blood sample was
not obtained at the first attempt, and 1 was of unknown age.
Samples were excluded for 42 subjects infected with HIV, 17 with
malaria parasitaemia, 17 taking antibiotics and 5 severely mal-
nourished subjects. All subjects were afebrile. Twenty results
failed internal quality assurance. Of the 539 subjects whose
lymphocyte subset data were included in the analysis, 256
(47.5%) were male and 283 female with a sex imbalance in
some groups.Absolute lymphocyte subset concentrations
Total leukocyte and total lymphocyte concentrations peaked at
12 to 18 months and then gradually fell by a factor of 2 and 3,
respectively, to adult levels (Table I). This trend was followed by
B and T lymphocytes, and CD41, CD81, and gdT-cell subsets,
with a 10-fold difference in B-cell and 2-fold to 3-fold difference
in T-cell and T-cell subset median concentrations at 12 to 18
months compared with adults. NK-cell levels varied minimally
throughout life. Total leukocyte, lymphocyte, and lymphocyte
subset concentrations did not fall away in old age.Relative lymphocyte subset values
Considering lymphocyte subset values as percentages of the
total lymphocyte count removed much of the age-related varia-
tion observed with absolute concentrations (Table II), and for this
reason, CD41 T-lymphocyte percentages are considered a more
appropriate measurement of CD4 count than absolute concentra-
tions in children under 5 years.10 Nevertheless, median B-lym-
phocyte percentages decreased in the first 5 years of life from
30% to 22%, whereas T-lymphocyte percentages increased
from 58% to 68%. CD41 T-lymphocyte percentages, although
ranging from 35% to 39% in children under 5 years, did not
vary consistently with age. By contrast, CD81 T-lymphocyte per-
centages increased from 19% to 25%.
As a consequence of these lowCD41 T-lymphocyte percentages
in children under 5 years, 35% (38) of 109 children age less than
1 year had values 35% for this age group, the WHO threshold
for immunodeficiency in HIV-infected children, with 18 meeting
the criterion for mild (CD41 30% to 35%), 17 for advanced
TABLE I. Absolute lymphocyte subset concentrations by age in venous blood from healthy Malawians
Age groups
Subset
0-6 mo
(n 5 58)
6-12 mo
(n 5 51)
12-18 mo
(n 5 46)
18-24 mo
(n 5 45)
2-3 y
(n 5 46)
3-5 y
(n 5 42)
5-10 y
(n 5 52)
10-15 y
(n 5 49)
15-20 y
(n 5 51)
20-60 y
(n 5 49)
>60 y
(n 5 50)
P value for
linear trend*
Male:female 21:37 20:31 27:19 29:16 27:19 21:21 26:26 14:35 26:25 23:26 22:28
Total leukocytes 9.4 9.7 10.95 9.4 8.0 8.2 6.5 5.7 5.2 5.0 5.65 <.001
(6.2, 15.3) (8.1, 14.2) (7.1, 15.7) (6.5, 13.2) (6.5, 11.5) (6.6, 9.8) (4.7, 10.8) (3.9, 8.1) (3.7, 7.3) (3.9, 7.2) (4.35, 6.95)
Total lymphocytes 5.45 6.3 7.0 5.4 4.25 3.7 3.1 2.8 2.1 2.0 2.4 <.001
(3.7, 9.2) (4.5, 9.6) (4.4, 9.3) (3.55, 7.4) (2.7, 6.0) (2.6, 5.1) (2.2, 4.9) (1.9, 3.8) (1.7, 3.2) (1.4, 2.9) (1.75, 2.95)
B lymphocytes 1.5 1.8 1.9 1.3 1.0 0.7 0.5 0.4 0.3 0.2 0.2 <.001
(CD191) (0.7, 2.8) (1.2, 2.9) (1.0, 3.5) (0.7, 2.4) (0.5, 1.5) (0.4, 1.3) (0.3, 0.8) (0.2, 0.7) (0.2, 0.5) (0.1, 0.3) (0.1, 0.4)
T lymphocytes 3.4 3.9 4.0 3.3 2.9 2.4 2.1 1.9 1.5 1.4 1.6 <.001
(CD31) (2.2, 6.1) (2.7, 5.6) (2.1, 5.5) (2.4, 4.8) (1.7, 4.5) (1.8, 3.7) (1.4, 3.4) (1.3, 2.7) (1.1, 2.4) (0.9, 2.1) (1.2, 2.2)
CD41 T lymphocytes 2.0 2.2 2.2 1.8 1.7 1.4 1.2 1.1 0.9 0.8 1.0 <.001
(CD31CD41) (1.3, 4.2) (1.6, 3.3) (1.2, 3.9) (1.2, 2.7) (1.0, 2.6) (0.9, 2.0) (0.8, 2.1) (0.8, 1.7) (0.6, 1.2) (0.5, 1.2) (0.6, 1.3)
CD81 T lymphocytes 1.0 1.4 1.4 1.3 1.0 0.9 0.8 0.7 0.6 0.6 0.5 <.001
(CD31CD81) (0.6, 2.1) (0.8, 2.3) (0.8, 2.3) (0.7, 2.0) (0.6, 1.6) (0.6, 1.5) (0.5, 1.2) (0.4, 1.1) (0.4, 1.0) (0.3, 1.0) (0.3, 0.9)
gdT lymphocytes 0.2 0.2 0.3 0.2 0.2 0.2 0.2 0.1 0.1 0.1 0.1 <.001
(CD31TCRgd1) (0.1, 0.4) (0.1, 0.5) (0.1, 0.7) (0.1, 0.4) (0.1, 0.4) (0.1, 0.4) (0.1, 0.3) (0.1, 0.3) (0.1, 0.2) (0.0, 0.2) (0.0, 0.1)
NK cells 0.4 0.4 0.4 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.4 .54
(CD3-CD16/561) (0.2, 1.0) (0.2, 0.7) (0.2, 1.2) (0.2, 0.7) (0.2, 0.8) (0.1, 0.6) (0.1, 0.9) (0.1, 0.6) (0.1, 0.5) (0.1, 0.7) (0.2, 0.8)
Values are medians (10th and 90th centiles) 3 103 cells/mL venous blood.
*Calculated by using actual ages in months.
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ficiency.2 Eighteen percent (25) of 137 children age 1 to 3 years had
CD41 T-lymphocyte percentages 30%, the threshold for immu-
nodeficiency in this age group, with 16 meeting the criterion for
mild (CD41 25% to 30%), 6 for advanced (CD41 20% to 24%),
and 3 for severe (CD41 < 20%) immunodeficiency. Only 1 of 45
children age 3 to 5 years had CD41 T-lymphocyte percentages
25% for this age group, the WHO threshold for
immunodeficiency.
Median CD41 to CD81 T-lymphocyte ratio (CD4:CD8 ratio)
varied between 1.4 and 2.0 across age groups. Eleven percent
(60/543) of all subjects and 13% (20) of 155 children age less
than 18 months had a ratio <1.0, which has been associated with
HIV infection.10 There was little variation between T, B, and
NK–lymphocyte subsets in adults (20-60 years) and the elderly
(over 60 years), although the CD191CD271memory B-cell popu-
lation increased throughout life to a peak of 41% in old age.Variation of lymphocyte subsets with age and sex
Log transformation resulted in approximately normal distribu-
tions for all values except percentage memory B lymphocytes.
There was very strong evidence for linear trend with age for all
parameters measured (P< .001), except NK-lymphocyte absolute
counts and CD4:CD8 ratio. There was some evidence for a qua-
dratic relationship between age and CD4:CD8 ratio (P 5 .05).
Total leukocytes and total lymphocyte concentrations, together
with all absolute lymphocyte subset concentrations and B and
gdT–lymphocyte percentages and CD4:CD8 ratio, decreased
with age, whereas T-lymphocyte and CD41 and CD81T-lympho-
cyte subsets and NK-lymphocyte andmemory B-lymphocyte per-
centages increased with age (test for linear trend P <.001 for all
parameters). There was some evidence of a quadratic rather than
linear fit for absolute lymphocyte subset concentrations, with
counts starting to increase in the oldest group. Using actual age,
age by group, or themidpoint of age by group gave similar results.Overall, females had significantly higher CD41 T-lymphocyte
percentages than males (geometric mean, 39.8% and 36.9%, re-
spectively;P< .001), whereas males had higher CD81T-lympho-
cyte percentages than females (geometric mean, 24.15% and
22.7%, respectively; P 5 .009). As a consequence, females
had higher CD4:CD8 ratios than males (geometric mean, 1.75
compared with 1.53; P < .001), although there was no significant
difference in percentage or absolute T or B–lymphocyte
concentrations or total lymphocyte count. The difference in
geometric mean absolute CD41 (1491 cells/mL for females
compared with 1321 cells/mL for males; P < .001) but not CD81
T-lymphocyte concentrations between the sexes was statistically
significant. No age-related differences in sex were identified, and
individual group sizes were too small to demonstrate statistically
significant differences within each age group.DISCUSSION
In this studywe have enumerated lymphocyte subsets in venous
blood from more than 500 healthy HIV-uninfected Malawians
stratified by age. Our results showmany similarities to those from
studies conducted in developed countries.11-14 Total lymphocyte
concentrations, together with total B-cell and T-cell/T-cell subset
concentrations peaked in the first 2 years of life, then decreased
through childhood to adulthood, whereas NK-cell concentrations
were relatively constant. Lymphocyte subset values for adults
were remarkably similar to those from adults in developed
countries.
Total lymphocyte concentrations are higher in early childhood
in Malawian children compared with children in developed
countries and decrease to similar levels around 5 years of age.
This difference appears to be the result of higher B-cell concen-
trations in early childhood in the Malawian population. Total
T-cell concentrations are very similar in African and western
children, but the peak median CD41 T-cell concentration is lower
(2.2 3 103/mL compared with 2.85 3 103/mL) and CD81 T-cell
TABLE II. Percentage lymphocyte subset concentrations by age in venous blood from healthy Malawians
Age groups
Subset
0-6 mo
(n 5 58)
6-12 mo
(n 5 51)
12-18 mo
(n 5 46)
18-24 mo
(n 5 45)
2-3 y
(n 5 46)
3-5 y
(n 5 42)
5-10 y
(n 5 52)
10-15 y
(n 5 49)
15-20 y
(n 5 51)
20-60 y
(n 5 49)
>60 y
(n 5 50)
P value for
linear trendz
Male:female 21:37 20:31 27:19 29:16 27:19 21:21 26:26 14:35 26:25 23:26 22:28
B lymphocytes 29 30 27 25 22 22 17 14 13 9 9 <.001
(CD191) (16, 38) (21, 38) (18, 39) (17, 36) (13, 27) (15, 29) (12, 24) (11, 21) (8, 18) (6, 14) (5, 16)
Memory B cells 4 8 10 17 22 22 28 28 31 38 41 <.001
(CD191CD271)* (3, 7) (4, 13) (6, 19) (10, 25) (11, 30) (14, 31) (15, 40) (16, 40) (18, 44) (19, 59) (24, 64)
T lymphocyte 58 61 61 66 66 68 71 71 71 73 69 <.001
(CD31) (50, 72) (52, 71) (48, 70.5) (54, 74) (61, 76) (58, 77) (59, 79) (59, 79) (61, 77) (63, 83) (57, 78)
CD41 T lymphocytes 39 36 35 38 39 37 40 41 41 41 42 <.001
(CD31CD41) (29, 49) (27, 44) (23, 45) (27, 49) (32, 46) (31, 47) (29, 49) (35, 52) (31, 48) (29, 51) (33, 52)
CD81 T lymphocytes 19 22.5 22 24 24 25 25 24 25 28 23 .002
(CD31CD81) (13, 25) (15, 32) (16, 35) (15, 32) (18, 32) (18, 34) (18, 32) (17, 34) (19, 35) (20, 37) (17, 35)
gdT lymphocytes 3 4 4 4 4 5 5 6 5 5 3 .001
(CD31TCRgd1) (1, 5) (2, 8) (2, 7) (3, 7) (3, 8) (3, 9) (3, 9) (3, 9) (3, 9) (2, 10) (1, 8)
NK cells 9 6 6 7 9 8 8 9.5 12 16 17 .001
(CD3-CD16/561) (4, 16) (4, 11) (3, 15) (3, 12) (5, 15) (4, 15) (3, 22) (5, 19) (5, 23) (6, 26) (8, 32)
CD4:CD8 2.0 1.6 1.6 1.5 1.6 1.5 1.6 1.8 1.6 1.4 1.8 .98
T-lymphocyte ratio (1.3, 3.6) (0.9, 2.7) (0.8, 2.9) (1.0, 2.6) (1.0, 2.3) (1.0, 2.4) (1.1, 2.3) (1.1, 2.6) (1.0, 2.3) (0.9, 2.3) (1.1, 2.8)
Values are medians (10th and 90th centiles) presented as percentage of total lymphocyte concentration, except *as percentage of total B-cell concentration, and as ratio of CD41 T
lymphocytes to CD81 T lymphocytes.
Calculated by using actual ages in months.
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mL) among Malawian children compared with children from
developed countries.11
There are also differences in the relative sizes of lymphocyte
subsets. Whereas in developed countries, T-lymphocyte percent-
ages and B-lymphocyte percentages are stable in the first
5 years of life at around 65% and 24%, respectively, in Malawi,
T-lymphocyte percentages rise from 58% to 68%, and
B-lymphocyte percentages fall from 30% to 22% during this
period. These findings, together with a rise in CD81 T-lympho-
cyte percentages from 0 to 5 years, mean that CD41 T-lympho-
cyte percentages in African children are low in the first year of
life and remain relatively stable between 35% and 39% up to
5 years of age. In contrast, CD41 T-lymphocyte percentages
in developed countries fall from around 46% to 38% in the first
5 years. We speculate that high B-cell and CD81 T-cell numbers
in African children under 2 years may be associated with
widespread infection with malaria and cytomegalovirus.
Although there are a lack of published reports from Africa
describing variations in T, B, and NK–lymphocyte subset data
with age, CD41 and CD81T-lymphocyte subsets have previously
been studied in African children in isolation from B and NK cells.
In Nairobi, Kenya, CD41 T-lymphocyte percentages in children
under 1 year old were very similar to those from Malawi
(39.9% up to 3 months and 36.5% from 4 to 12 months), but ap-
proximately 4% lower in children age 1 to 5 years, with median
values varying from 32.9% to 35.0%.21 Median CD41 T-lympho-
cyte percentages in Ugandan children under 1 year old were found
to be particularly low at 31.9%, with values in children from 1 to 5
years very similar to those from Kenya (33.5%).16 These studies
indicate that the low CD41 T-lymphocyte percentages in Mala-
wian children are not unusual for Africa.
CD81 T-lymphocyte percentages were higher in Kenyan chil-
dren compared with Malawian children (approximately 25% in
children under 1 year old and 30% in children age 1 to 5 years),21
although surprisingly lower in Ugandan children (31.9% inchildren under 1 year old and 33.5% in children age 1 to 5
years).16 This finding suggests a relative expansion of B and
NK–cell compared with T-cell populations in Ugandan children
that cannot be confirmed because of a lack of data on these lym-
phocyte subpopulations. Absolute CD41 and CD81 T-lympho-
cyte subsets were broadly similar in Malawian and Kenyan21
children under 5 years, but lower in Ugandan children.16
The lack of decline in lymphocyte subset numbers among
elderlyMalawians suggests that this aspect of the immune system
is protected from the effects of immune senescence. By contrast, a
study among Italians age 4 to 106 years found decreased B and
T–lymphocyte concentrations in old age,26 although 19% (26) of
the participants were centenarians, whereas the oldest Malawian
in our study was 92 years old. Our finding of increasing memory
compartment of B cells with age is consistent with a previous
report from Europe.27
As has previously been found in a developed-world popula-
tion,11 age was highly significant in lymphocyte subset count re-
gressions, and in this study, significance was detected with all
subsets investigated both for absolute and percentage concentra-
tions except NK-cell absolute counts and CD4:CD8 ratios. The
unexpected finding from the statistical analysis was the highly
significant difference in CD41 and CD81 T-lymphocyte percent-
ages between the sexes, with high relative CD41 counts in
females and high CD81 counts in males.
Reporting of sex differences in lymphocyte subset concentra-
tions in previous studies across ages has been variable. Where
given, differences have been inconsistent between studies. One
western immunophenotyping study in children found a significant
difference with sex only for CD41 T-cell percentage,11 whereas a
study from Ethiopia found such a difference in adults but not chil-
dren.16 A recent study in Kenyan adults found that T, B, and NK–
lymphocyte and T-lymphocyte subset absolute and percentage
numbers were higher in women than men except for NK and
CD81 T–cell percentages.19 In contrast, a separate study among
East and Southern African adults from a variety of sites found
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study was not designed to explore sex differences in lymphocyte
subsets, and this issue warrants further investigation.
Our findings have important implications for current guidelines
regarding the immunologic assessment of HIV-infected children
in resource-limited settings.2 Although median and centile values
determined in the current study were from healthy HIV-unin-
fected African children, the relative lowCD41T-lymphocyte per-
centages in children under 1 year old meant that 35% of these
children met the CD4 criterion for immunodeficiency in HIV-in-
fected children. Interestingly, 10% of healthy American children
under 1 year of age also met this criterion.11 Our finding that
CD41 T-lymphocyte percentages were relatively stable through
5 years of age in Malawian children contrasts with the WHO
threshold values for immunodeficiency, which fall with age in a
stepwise manner from 0 to 5 years. The data presented suggest
that caution should be exercised when applying current guidelines
for the immunologic assessment of HIV-infected African children
in isolation and underline the importance of using CD4 measure-
ments in conjunction with clinical assessment.2
HIV-infected children in South Africa under 12 months of age
have recently been shown to have a significantly improved
clinical outcome if started early on ART regardless of CD41
T-lymphocyte percentage.28 This has led to a change in national
policy and guidelines in Malawi29 as well as the US National
Institutes of Health30 and European31 guidelines on the manage-
ment of HIV-infected children such that all children under 12
months of age with proven infection should be commenced on
ART. Therefore, the findings from the current study are unlikely
to affect treatment of children in this age group.
ACD4:CD8 T-lymphocyte ratio less than 1.0 is associated with
HIV infection and has been proposed as a parameter for the
diagnosis of HIV in African children under 18 months old,32
where results of HIV rapid tests can be complicated by maternal
antibody to HIV.10,32 With decreased CD41 and increased CD81
T-lymphocyte concentrations in young children in this study com-
pared with results from developed countries, 13% of Malawian
children under 18 months had a CD4:CD8 ratio <1.0. Therefore,
a CD4:CD8 ratio <1.0 is not specific for HIV infection, and this
parameter should be used with caution in HIV diagnosis.
In conclusion, our findings provide a comprehensive descrip-
tion of principle lymphocyte subsets and T-lymphocyte subsets
with age in a healthy African population. The findings suggest
that caution should be exercised when assessing the immunologic
status of HIV-infected African children using current WHO
guidelines and serve as a reminder to clinicians to take into
consideration the clinical status of the child alongside laboratory
parameters. Further studies from elsewhere in Africa are required
to confirm whether the low CD41 T-lymphocyte percentages
found in HIV-uninfected children in this study in Malawi and in
previous studies from Kenya and Uganda are a consistent finding
throughout the continent. In addition, the sex variation in CD41
T-lymphocyte percentage and absolute concentrations deserves
further investigation, in particular to determine whether higher
values in females occur at all ages.
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Clinical implications: CD41T-lymphocyte percentages in young
African children are low compared with those in children from
developed countries, and this must be taken into account when
assessing the severity of HIV-related immunodeficiency in these
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